17 August 2023
Eden Research
("Eden" or "the Company")
Result of General Meeting and Capital Raising update
Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, is pleased to announce that all resolutions put forward to shareholders at the Company's General Meeting held earlier today were duly passed.
The total number of votes received by proxy on each resolution, as more fully disclosed in the Notice of Meeting available on the Company's website, was as follows:
| # | Resolution | For | % | Against | % | Withheld |
| 1 | Grant authority to the Directors to allot Ordinary Shares | 129,273,794 | 99.79 | 269,322 | 0.21 | 13,950 |
| 2 | Disapply statutory pre-emption rights on allotment of shares* | 129,183,794 | 99.72 | 359,322 | 0.28 | 13,950 |
| 3 | Grant authority to cancel share premium account* | 129,157,112 | 99.76 | 316,252 | 0.24 | 83,702 |
Notes:
· * Denotes a Special Resolution.
· A vote Withheld is not a vote in law and is not counted in the calculation of the votes cast For or Against the resolution, nor in the calculation of the percentage of issued share capital voted for any resolution.
· Votes For and Against are expressed as a percentage of votes validly cast for that resolution by proxy, excluding any Withheld votes.
Capital Raising update
In the announcement made by the Company on 28 July 2023 regarding its Capital Raising, it was stated that "The Placing of the Conditional Placing Shares is conditional, inter alia, on (i) the approval of the Resolutions at the General Meeting, (ii) the Advanced Assurance being obtained from HMRC, (iii) the Capital Reduction becoming effective and (iv) Second Admission."
In addition to the Resolutions having been approved at the General Meeting today, the Company is pleased to confirm that it has also obtained the Advanced Assurance from HMRC required for the Conditional Placing.
The expected timetable for the satisfying the remaining conditions of the Conditional Placing is as follows:
| Expected date for final hearing and confirmation of the Capital Reduction by the Court | 12 September |
| Expected date that the Capital Reduction become effective | 14 September |
| Second Admission | Expected second half of September |
| Second Admission Long Stop Date | 8 a.m. on 20 October |
For further information contact:
| Eden Research plc | |
| Sean Smith
| 01285 359 555 |
| | |
| Cenkos Securities plc (Nominated advisor and broker) |
|
| Giles Balleny / Max Gould (corporate finance)
| 020 7397 8900 |
| | |
| Hawthorn Advisors (Financial PR) |
|
| Simon Woods Felix Meston |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
